• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射后视网膜裂孔和孔源性视网膜脱离:其患病率及病例报告

Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports.

作者信息

Karabag Revan Yildirim, Parlak Melih, Cetin Gölgem, Yaman Aylin, Osman Saatci A

机构信息

Department of Ophthalmology, Dokuz Eylul University Medical School, Izmir, Turkey;

Department of Ophthalmology, Klinikum Konstanz, Konstanz, Germany.

出版信息

Digit J Ophthalmol. 2015 Mar 23;21(1):8-10. doi: 10.5693/djo.01.2014.07.001. eCollection 2015.

DOI:10.5693/djo.01.2014.07.001
PMID:27330458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4902634/
Abstract

PURPOSE

To report the prevalence of postoperative retinal tear or rhegmatogenous retinal detachment secondary to intravitreal injections.

METHODS

Surgical and medical records of patients who received intravitreal injections at the practice of a single retina specialist from January 2004 to May 2013 and who were followed for at least 6 months were investigated retrospectively.

RESULTS

During the study period, a total of 3,907 intravitreal injections were performed in 1,049 eyes of 784 patients (416 males [47%]). The mean number of injections per eye was 3.72 ± 3.43 (range, 1-22). The mean age of the participants was 67.03 ± 13.56 (range, 5-94 years). The mean follow-up time was 31.98 ± 22.86 months (range, 6-144 months). Retinal break or rhegmatogenous retinal detachment occurred in 3 injections of 3 eyes, yielding an overall prevalence of 0.077% per injection and 0.29% per eye.

CONCLUSIONS

Retinal tear and rhegmatogenous detachment are rare complications of intravitreal injection. Precautions should be taken especially in patients having predisposing conditions, such as high myopia, or any other vitreoretinal disorders.

摘要

目的

报告玻璃体内注射继发的术后视网膜裂孔或孔源性视网膜脱离的患病率。

方法

回顾性调查2004年1月至2013年5月在一名视网膜专科医生处接受玻璃体内注射且随访至少6个月的患者的手术和医疗记录。

结果

在研究期间,共对784例患者(416例男性[47%])的1049只眼进行了3907次玻璃体内注射。每只眼的平均注射次数为3.72±3.43(范围1 - 22次)。参与者的平均年龄为67.03±13.56(范围5 - 94岁)。平均随访时间为31.98±22.86个月(范围6 - 144个月)。3只眼中的3次注射发生了视网膜裂孔或孔源性视网膜脱离,每次注射的总体患病率为0.077%,每只眼为0.29%。

结论

视网膜裂孔和孔源性脱离是玻璃体内注射的罕见并发症。对于有高度近视等易感因素或任何其他玻璃体视网膜疾病的患者,应特别注意预防。

相似文献

1
Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports.玻璃体内注射后视网膜裂孔和孔源性视网膜脱离:其患病率及病例报告
Digit J Ophthalmol. 2015 Mar 23;21(1):8-10. doi: 10.5693/djo.01.2014.07.001. eCollection 2015.
2
Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.在医院环境中,主要由实习医生和护士进行的38503次玻璃体内注射雷珠单抗的安全性研究。
Acta Ophthalmol. 2015 Mar;93(2):122-5. doi: 10.1111/aos.12589. Epub 2014 Nov 17.
3
Myopia as a risk factor for subsequent retinal tears in the course of a symptomatic posterior vitreous detachment.近视作为有症状的玻璃体后脱离过程中后续视网膜裂孔的一个风险因素。
BMC Ophthalmol. 2017 Dec 1;17(1):226. doi: 10.1186/s12886-017-0629-6.
4
Surgical repair of rhegmatogenous retinal detachment after treatment for retinoblastoma.视网膜母细胞瘤治疗后孔源性视网膜脱离的手术修复
Ophthalmology. 1998 Nov;105(11):2134-9. doi: 10.1016/S0161-6420(98)91139-3.
5
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.抗血管内皮生长因子眼内注射后孔源性视网膜脱离的发生率。
Acta Ophthalmol. 2011 Feb;89(1):70-5. doi: 10.1111/j.1755-3768.2010.02064.x. Epub 2010 Dec 22.
6
Rhegmatogenous retinal detachment in phakic eyes after posterior chamber phakic intraocular lens implantation for severe myopia.高度近视患者后房型有晶状体眼人工晶状体植入术后晶状体源性视网膜脱离
Ophthalmology. 2005 Apr;112(4):580-5. doi: 10.1016/j.ophtha.2004.09.025.
7
[Outcome after vitrectomy in rhegmatogenous retinal detachment and dense vitreous opacities].[孔源性视网膜脱离合并致密玻璃体混浊行玻璃体切除术后的预后]
Klin Monbl Augenheilkd. 1997 Dec;211(6):369-74. doi: 10.1055/s-2008-1035150.
8
[Retinal detachment caused by macular holes in patients with severe myopia: results of intravitreal injection of pure C3F8].[高度近视患者黄斑裂孔所致视网膜脱离:玻璃体腔内注射纯C3F8的结果]
J Fr Ophtalmol. 1996;19(8-9):491-5.
9
Rhegmatogenous retinal detachment following treatment for retinoblastoma.视网膜母细胞瘤治疗后发生的孔源性视网膜脱离。
J Pediatr Ophthalmol Strabismus. 2010 Nov-Dec;47(6):349-55. doi: 10.3928/01913913-20091218-03. Epub 2009 Dec 23.
10
Retinal Pigment Epithelial Tear After Intravitreal Ranibizumab Treatment for Retinal Angiomatous Proliferation.玻璃体内注射雷珠单抗治疗视网膜血管瘤样增生后发生的视网膜色素上皮撕裂
Am J Ophthalmol. 2015 Nov;160(5):1000-1005.e2. doi: 10.1016/j.ajo.2015.07.023. Epub 2015 Jul 22.

引用本文的文献

1
Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature.玻璃体内地塞米松植入物在玻璃体视网膜手术中的应用:文献综述
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 20. doi: 10.1007/s00417-025-06797-7.
2
Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series.与玻璃体内注射贝伐单抗相关的无菌性眼内炎患者的临床特征、处理方法和转归:回顾性病例系列研究。
Int Ophthalmol. 2024 May 5;44(1):216. doi: 10.1007/s10792-024-03134-5.
3
Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial.玻璃体内注射贝伐单抗联合普萘洛尔治疗新生血管性年龄相关性黄斑变性(BEVALOL研究):一项I期临床试验
Int J Retina Vitreous. 2023 Apr 13;9(1):28. doi: 10.1186/s40942-023-00460-1.
4
Computational Modeling of Ophthalmic Procedures: Computational Modeling of Ophthalmic Procedures.眼科手术的计算建模:眼科手术的计算建模。
Am J Ophthalmol. 2022 Sep;241:87-107. doi: 10.1016/j.ajo.2022.03.023. Epub 2022 Mar 28.
5
Commentary: Iatrogenic retinal breaks secondary to jet stream injury.评论:喷射流损伤继发的医源性视网膜裂孔
Indian J Ophthalmol. 2022 Mar;70(3):907-908. doi: 10.4103/ijo.IJO_2746_21.
6
Jet stream related iatrogenic retinal breaks during vitreo-retinal surgery.喷气相关医源性视网膜裂孔在玻璃体视网膜手术期间。
Indian J Ophthalmol. 2022 Mar;70(3):902-907. doi: 10.4103/ijo.IJO_1918_21.
7
Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization.近视性脉络膜新生血管的真实世界抗血管内皮生长因子治疗结果
Clin Ophthalmol. 2021 Jun 25;15:2753-2758. doi: 10.2147/OPTH.S311816. eCollection 2021.
8
Iatrogenic Retinal Penetration from Intravitreal Injections.玻璃体腔内注射所致医源性视网膜穿透
Case Rep Ophthalmol. 2021 Apr 12;12(1):248-253. doi: 10.1159/000512695. eCollection 2021 Jan-Apr.
9
Characteristics and surgical outcomes of rhegmatogenous retinal detachments that develop after intravitreal injections.眼内注射后发生的孔源性视网膜脱离的特征和手术结果。
Jpn J Ophthalmol. 2021 Jul;65(4):492-496. doi: 10.1007/s10384-021-00834-8. Epub 2021 Mar 21.
10
Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels.通过载药油凝胶实现亲水性药物的眼部给药。
Eur J Pharm Sci. 2021 Mar 1;158:105634. doi: 10.1016/j.ejps.2020.105634. Epub 2020 Nov 1.

本文引用的文献

1
Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.雷珠单抗 0.5mg 治疗糖尿病性黄斑水肿 2 年的安全性和疗效:RESTORE 扩展研究的中期分析。
Ophthalmology. 2013 Oct;120(10):2004-12. doi: 10.1016/j.ophtha.2013.02.019. Epub 2013 May 29.
2
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.雷珠单抗治疗糖尿病黄斑水肿的长期疗效:两项 III 期临床试验(RISE 和 RIDE)的 36 个月结果。
Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.
3
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.VEGF Trap-Eye 治疗视网膜中央静脉阻塞继发黄斑水肿的 III 期 GALILEO 研究:6 个月结果。
Br J Ophthalmol. 2013 Mar;97(3):278-84. doi: 10.1136/bjophthalmol-2012-301504. Epub 2013 Jan 7.
4
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.玻璃体内注射阿柏西普(抗 VEGF 融合蛋白)治疗湿性年龄相关性黄斑变性。
Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17.
5
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性:两年结果。
Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.
6
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.抗血管内皮生长因子 Trap-Eye 治疗视网膜中央静脉阻塞继发黄斑水肿的三期 COPERNICUS 研究:6 个月结果。
Ophthalmology. 2012 May;119(5):1024-32. doi: 10.1016/j.ophtha.2012.01.042. Epub 2012 Mar 21.
7
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的持续获益:一项 III 期研究的 12 个月结果。
Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.
8
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.雷珠单抗治疗视网膜分支静脉阻塞继发黄斑水肿的持续获益:一项 III 期研究的 12 个月结果。
Ophthalmology. 2011 Aug;118(8):1594-602. doi: 10.1016/j.ophtha.2011.02.022.
9
Severe adverse events after cataract surgery among medicare beneficiaries.医疗保险受益人群白内障手术后的严重不良事件。
Ophthalmology. 2011 Sep;118(9):1716-23. doi: 10.1016/j.ophtha.2011.02.024. Epub 2011 Jun 2.
10
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.抗血管内皮生长因子眼内注射后孔源性视网膜脱离的发生率。
Acta Ophthalmol. 2011 Feb;89(1):70-5. doi: 10.1111/j.1755-3768.2010.02064.x. Epub 2010 Dec 22.